A novel ultrasensitive LC-MS/MS assay for quantification of intracellular raltegravir in human cell extracts

Journal of Pharmaceutical and Biomedical Analysis

Volumn 70, Issue , 2012, Pages 378-387

  Robbins, Brian L ^a   Nelson, Sarah R ^a   Fletcher, Courtney V ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

HIV; Integrase inhibitor; Intracellular; LC MS MS; Raltegravir

Indexed keywords

CELL EXTRACT; RALTEGRAVIR;

ARTICLE; CONTROLLED STUDY; DILUTION; DRUG DETERMINATION; DRUG STABILITY; HUMAN; HUMAN CELL; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; ROOM TEMPERATURE;

CALIBRATION; CELL EXTRACTS; CENTRIFUGATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; HIV INTEGRASE INHIBITORS; HUMANS; LEUKOCYTES, MONONUCLEAR; LIMIT OF DETECTION; LINEAR MODELS; METHANOL; PYRROLIDINONES; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 84866261116     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.05.035     Document Type: Article

References (19)

1. Croxtall J., Lyseng-Williamson K., Perry C. Raltegravir. Drugs 2008, 68:131-138.
2. Found at: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDS%20Activities/ucm124040.htm.
3. Lennox J.L., DeJesus E., Lazzarin A., Pollard R.B., Madruga J.V., Berger D.S., Zhao J., Xu X., Williams-Diaz A., Rodgers A.J., Barnard R.J., Miller M.D., DiNubile M.J., Nguyen B.Y., Leavitt R., Sklar P., STARTMRK investigators Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009, 374:796-806.
4. Rockstroh J.K., Lennox J.L., Dejesus E., Saag M.S., Lazzarin A., Wan H., Walker M.L., Xu X., Zhao J., Teppler H., Dinubile M.J., Rodgers A.J., Nguyen B.Y., Leavitt R., Sklar P., STARTMRK Investigators Long term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment naïve human immunodeficiency virus-1-infected patients: week 156 results from STARMRK. Clin. Infect. Dis. 2011, 53:807-816.
5. Markowitz M., Morales-Ramirez J.O., Nguyen B.Y., et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 2006, 43:509-515.
6. ter Heine R., Mulder J., van Gorp E., Wagenaar J., Beijnen J., Huitema A. Plasma and intracellular pharmacokinetics of new antiretroviral drugs. Br. J. Clin. Pharmacol. 2010, 69:476-483.
7. Brainard D., Wenning L., Stone J., Wagner J., Iwamoto M. Profile of raltegravir an HIV-1 integrase strand transfer inhibitor. J. Clin. Pharmacol. 2011, 203:258-262.
8. Molto J., Valle M., Back D., Cedeno S., Watson V., Leptrott N., Egan D., Miranda C., Barbanoj M., Clotet B. Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800milligrams) in HIV-infected patients. Antimicrob. Agents Chemother. 2011, 55:72-75.
9. Found at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf.
10. King T., Bushman L., Anderson P., Delahunty T., Ray M., Fletcher C.V. Quantitation of zidovudine triphosphate concentrations from human peripheral blood mononuclear cells by anion exchange solid phase extraction and liquid chromatography-tandem mass spectrometry: an indirect quantitation methodology. J. Chromatogr. B 2006, 831:248-257.
11. Robbins B., Poston P., Neal E., Slaughter C., Rodman J. Simultaneous measurement of intracellular triphosphate metabolites of zidovudine, lamivudine and abacavir (carbovir) in human peripheral blood mononuclear cells by combined anion exchange solid phase extraction and LC-MS/MS. J. Chromatogr. B 2007, 850:310-317.
12. King T., Bushman L., Anderson P., Kiser J., Ray M., Delahunty T., Fletcher C.V. Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. J. Chromatogr. B 2006, 843:147-156.
13. Robbins B., Connelly M., Marshall D., Srinivas R., Fridland A. A human T lymphoid cell variant resistant to the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine shows a unique combination of a phosphorylation defect and increased efflux of the agent. Mol. Pharmacol. 1995, 47:391-397.
14. Strauss P., Sheehan J., Kashket E. Membrane transport by murine lymphocytes. J. Exp. Med. 1976, 144:1009-1021.
15. Andreasen P., Schaumburg B., Osterlind K., Vinten J., Gammeltoft S., Gliemann J. A rapid technique for separation of thymocytes from suspensions by centrifugation through silicone oil. Anal. Biochem. 1974, 59:610-616.
16. Krumpochova P., Kocurova A., Dolezel P., Mlejnek P. Assay for determination of daunorubicin in cancer cells with multidrug resistance phenotype. J. Chromatogr. B 2011, 879:1875-1880.
17. Lameh J., Chuang R., Israel M., Chuang L. Nucleoside uptake and membrane fluidity studies on N-trifluroracetyladriamycin-14-O-hemiadipate-treated human leukemia and lymphoma cells. Cancer Res. 1989, 49:2905-2908.
18. Simiele M., D'Avolio A., Baietto L., Siccardi M., Sciandra M., Agati S., Cusato J., Bonora S., Di Perri G. Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a Coulter counter to determine intracellular drug concentrations. Antimicrob. Agents Chemother. 2011, 55:2976-2978.
19. Jackson A., Watson V., Back D., Khoo S., Liptrott N., Egan D., Gedela K., Higgs C., Abbas R., Gazzard B., Boffito M. Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals. J. Acquir. Immune Defic. Syndr. 2011, 58:450-457.